The identification of patients with aggressive cancer who require immediate therapy is a health challenge in low-and middleincome countries. Limited pathology resources, high healthcare costs and large caseloads call for the development of advanced stand-alone diagnostics. Here, we report and validate an automated, low-cost point-of-care device for the molecular diagnosis of aggressive lymphomas. The device uses contrast-enhanced microholography and a deep learning algorithm to directly analyse percutaneously obtained fine-needle aspirates. We show the feasibility and high accuracy of the device in cells, as well as the prospective validation of the results in 40 patients clinically referred for image-guided aspiration of nodal mass lesions suspicious of lymphoma. Automated analysis of human samples with the portable device should allow for the accurate classification of patients with benign and malignant adenopathy.
M odern oncology requires tissue-specific diagnoses before appropriate therapies are initiated. These are commonly performed by image-guided tumour biopsy, fine-needle aspirates (FNAs), or liquid biopsies where samples are processed by conventional immunohistochemistry, flow cytometry and/or genetic analysis. These procedures can be costly and time-consuming, but nevertheless are essential to enable precision medicine. In most developed countries, there are sufficient numbers of pathologists (typically > 30 per million inhabitants) and related support structures for sample processing, analysis and interpretation to rarely encounter bottlenecks 1 . This picture is very different in low-and middle-income countries (LMICs) in Asia 1 and Africa; for example, several African countries report only one pathologist per million inhabitants 2 . Meanwhile, the global cancer burden is rising.
One of the specific health challenges in sub-Saharan Africa is the high prevalence of AIDS-related cancers (the 'second wave of AIDS') [3] [4] [5] . These include very aggressive cancers such as diffuse large B cell lymphoma (DLBCL) and Burkitt's lymphoma 6, 7 . Due to limited resources, a considerable proportion of these cases evade comprehensive evaluation or are not appropriately classified. Diagnosis and care are hampered by a lack of proper tissue specimens and diagnostic reagents, limited availability of trained pathologists/specialists and lack of access to care in rural settings. Although a good proportion of these cases are curable even in LMICs, windows of therapeutic opportunity are often missed 6, 8 . As a result, there is a need for low-cost, fast, accurate detection technologies to expedite the diagnosis of lymphomas (and other prevalent cancers) in these environments.
Recent advances in digital image sensors and mobile platforms (for example, smartphones, wearable electronics and microcomputers) have led to the development of digital point-of-care imaging systems that may address the lack or bottleneck of pathology specialists [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . The diagnostic potential of these systems has been demonstrated by successful detection of various biological objects (for example, tissues, cancer cells, sperm and parasites). However, most of these targets were identified via morphological features or a few defined markers. Detecting lymphoid cancers with portable imagers poses more technical challenges: (1) clonal neoplastic lymphoid cells exist on a background of normal lymphocytes in the blood; (2) target cells are generally small (similar to the size of blood cells); and (3) a diverse set of different surface markers need to be tested for disease classification. To address these challenges, clinical laboratories increasingly use flow cytometry despite its inherent limitations, such as high cost and under-diagnosing aggressive lymphomas due to the lack of accurate size measurements and fragility of large cells [21] [22] [23] . Portable fluorescence microscopes could be used to profile molecular markers, but their limited field of view (FOV) and need for expert interpretation make this approach less feasible 13, 19, 24 .
Digital holography enables microscopic bright-field imaging with a large FOV over mm 2 and a high spatial resolution for singlecell analysis 10, 12, [25] [26] [27] . In previous research, we showed that molecular specificity can be obtained by labelling large epithelial cells
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Articles NATure BiomedicAL eNgiNeeriNg with μ m-sized beads that change the cells' holographic patterns 11, 28 . However, for lymphoma diagnosis 28 , the number of beads per cell is limited due to much smaller lymphoma cells, and the approach is incompatible with analysing intracellular markers. To circumvent these drawbacks and enable the detection of intracellular proteins (for example, Ki67), we hypothesized that small-molecule chromogens would have to be used to modulate holographic patterns. Irrespective of the approach, there is currently no point-ofcare device for automated lymphoma diagnostics in LMICs.
Here, we developed an automated digital cellular analysis tool that enables analyses of specimens obtained from palpable mass lesions. Starting from microholography principles, we developed a contrast-enhanced micrography (CEM) that is simple, portable, robust, integrated and relatively low cost for the molecular diagnosis of lymphoma. The underpinning technology uses a high-resolution complementary metal-oxide-semiconductor (CMOS) image sensor to resolve target cells captured in a fluidic cartridge. Importantly, unlike digital microscopy, molecular specificity is obtained by staining cells with chromogen-labelled antibodies that generate holographic signatures rather than visual interpretation of cellular morphology. The assay occurs within disposable cassettes in which target cells are specifically captured and stained, thus minimizing the risk of exposure to healthcare providers or artefactual readouts from contaminants. Images containing up to 10,000 cells per FOV are detected by custom-developed deep learning algorithms and then reconstructed using either a cloud-based server within seconds or a local device within minutes. The end results include quantitative readouts of malignant cell number, cell size and differentiation between high-and low-grade subtypes based on specific marker expressions. We hypothesize that this approach would allow the detection and triaging of lymphomas into aggressive and indolent subtypes, each with vastly different therapeutic approaches and urgency. To test this paradigm, we performed a prospective clinical trial with 40 patients referred for aspiration and biopsy of enlarged lymph nodes (lymphadenopathy) detected by whole-body imaging. This trial was designed as a validation study and conducted before future role-out to LMIC settings.
Results

CEM for point-of-care diagnosis.
We designed the CEM device as a portable, stand-alone digital microholography system ( Fig. 1a and Supplementary Fig. 1 ). The device is equipped with: (1) a CMOS image sensor with a light-emitting diode for imaging; (2) a Raspberry Pi 3 module for cost-effective computing and image processing; (3) a wireless and Bluetooth unit for networking; and (4) a touchscreen for user-friendly operation. The CEM device is powered by either a corded power supply adaptor or a lithiumion battery pack for portable operation. Overall dimensions are 205 mm (L) × 120 mm (W) × 175 mm (H), and 1.4 kg in weight. The CEM assay for lymphoma diagnostics relies on immunostaining B cells captured inside a disposable microfluidic cartridge (Fig. 1b) . The cartridge's bottom glass surface is pre-functionalized with neutravidin to specifically capture B cells-labelled with biotinylated CD19/CD20 antibodies-in a given sample ( Supplementary  Fig. 2 ). This specific initial selection process measures captured B cell counts and sizes. Enriched B cells are then immunostained on-chip against κ or λ light chains or Ki67. While it is possible to interrogate many more molecular markers, we purposefully limit them to the most relevant panel that still identifies B cell lymphoma and distinguishes between aggressive and indolent lymphoma types ( Supplementary Fig. 3 ). To simplify analyses, we adapted deep learning technology using a convolutional neural network (CNN; Fig. 1c ) trained on > 5,000 holographic cellular lymphoma images ( Supplementary Fig. 4 ). The algorithm automatically detects captured B cells directly from holograms without computationally intensive image reconstruction.
Cell size and the degree of staining are then calculated for each captured cell and displayed with coloured circles.
Deep learning algorithm for cell detection. Figure 2a shows a hologram image overlaid with pseudo-colour circles showing the location, size and marker expression of each single cell. The images' FOV is about 5.7 mm × 4.3 mm-about 100 times larger than conventional microscope images using a 20× objective (numerical aperture = 0.4), yet image resolutions and sensitivities remain comparable ( Fig. 2a,b ). The deep learning algorithm identifies B cells based on their holographic signatures while excluding noncell objects (for example, dust, debris, artefacts, noise and so on; Supplementary Fig. 5 ). The algorithm's detection accuracy matches conventional image reconstruction ( Fig. 2c ). After 250 epochs, the training accuracy reached 99% ( Fig. 2d ). With the deep learning algorithm, the computational time was five times faster than image reconstruction of the entire FOV. Using a cloud-connected central graphic processing unit (GPU) server allowed reconstruction and analysis in less than 12 s for an average 10 MB PNG image. Even when the local Raspberry Pi computer is used without GPU, analysis of 1,000 cells can be completed in 5 min ( Fig. 2e ). The computational time can be as short as 60 s for smaller cell counts (in the range of 200 cells). This is particularly important while operating the assay in rural areas where wireless internet connection is often slow or unavailable. Irrespective of the reconstruction method, both modes are enabled in the device, which switches between them automatically depending on internet availability.
Assay validation. First, we validated the CEM assay using wellestablished lymphoma cell lines. Specifically, we used B cell (Daudi and DB) and T cell (Jurkat) cell lines to determine capture efficiency, size measurements, staining, sensitivity, specificity and reproducibility. B cell lymphoma cells exhibited a high capture efficiency of over 90%, while the non-specific binding of Jurkat cells was below 5% (Fig. 3a ). We observed a good correlation between the expected and measured captured cell counts for mixtures of Daudi and Jurkat cells with varying cell proportions (Pearson's correlation coefficient r = 0.97, P = 0.0013; Fig. 3b ). We performed size calibration using different sizes of microspheres (3, 6, 8 and 16 µ m) and again observed excellent correlation (Pearson's r = 0.99, P = 0.0020; Fig. 3c ). To enable immunostaining without the need for fluorescence, we tested different chromogenic substrates and identified one (ImmPACT VIP) that enabled the highest CEM contrast ( Fig. 4a ). This was used for all subsequent experiments. To validate CEM-based cellular profiling, we quantified the expression of three target markers (κ light chain, λ light chain and Ki67) on three different cell lines. In the case of Daudi, κ and Ki67 signals were high, while λ and Ki67 signals were dominant in DB. As expected, the T cell line (Jurkat) only showed a positive signal for Ki67 expression. These results are consistent with conventional flow cytometry analyses ( Fig. 4b) . To test the assay under more stringent environmental conditions, such as those found in many LMICs, we lyophilized antibodies and tested different storage conditions (− 20, 4, 25 and 37 °C). As summarized in Fig. 4c , lyophilization showed good reproducibility with CEM variability of < 5%.
Clinical studies. Following the preclinical validation studies, we proceeded to patient-oriented testing. We designed a prospective trial with 40 patients referred for clinically indicated image-guided aspiration and biopsy of mass lesions suspicious for lymphoma. All patients gave informed consent for extra FNA passes. All pre-procedural images were reviewed, and coaxial needles were placed under computed tomography or ultrasound guidance ( Supplementary Fig. 6 ). Samples for routine clinical testing included multiple (n = 4-8) 21G passes for flow cytometry and cytopathology followed by 19G tissue cores for histopathology (all processed by the Pathology Table 1 ). Figure 6a shows the decision tree for CEM-derived diagnoses of B cell lymphoma and benign adenopathy. The decision tree reflects a simplified algorithm for lymphoma diagnosis in LMICs based on the published literature 29 , World Health Organization guidelines 30, 31 and our own practical experience in pathology at the Massachusetts General Hospital. First, we determined whether the collected samples had sufficient cell counts for CEM analyses. If fewer than 100 cells per marker were present, we deemed the sample nondiagnostic, which occurred in only 1 of the 40 specimens. It should be noted that this number was higher for clinical flow cytometry, which was non-diagnostic in 10 of the 40 cases despite the higher number of FNA passes. Additionally, we set a secondary criterion that more than 10% of cells are positive for at least 1 of 3 markers (κ or λ light chains or Ki67) to ensure the adequacy of a given test ( Supplementary Fig. 3) .
A second sub-algorithm was used to determine whether a given patient had malignant lymphoma or benign adenopathy. This was deciphered by B cell population prevalence (> 20%) and clonality (κ and λ light chain expression; Fig. 6b ). Based on previous work and historical controls, we defined lymphoid clonality as (κ -λ )/ (κ + λ ) and characterized it as lymphoma when the ratio was greater than + 0.5 ± 0.05 (κ dominant) or less than − 0.5 ± 0.05 (λ dominant). For the 40 samples analysed, CEM showed an accuracy of 95% (37/39; 1 non-diagnostic) in detecting malignant lymphoma ( Fig. 6b and Table 1 ). The non-diagnostic case (case 5) offered too few B cell counts to accurately determine clonality. In comparison, a review of the official flow cytometry results, as interpreted by clinical hematopathologists, showed an accuracy of 87% (26/30; 10 nondiagnostic), with 3 false negatives and 1 false positive.
Furthermore, we used a combination of Ki67 staining and nuclear cell size measurements to determine whether each lymphoma case was aggressive or low grade. Among the 24 lymphoma samples tested, CEM correctly identified 21 cases (2 false negative and 1 non-diagnostic). For the 21 lymphoma cases ( Fig. 7a,b) , aggressive lymphomas were defined as having > 45% Ki67-positive cells ( Fig. 7c ) and/or having large fractions of large cell nuclei (> 15 µ m; Fig. 7d ). Using the above criteria, CEM correctly established the diagnosis of aggressive DLBCL in all 6 of the pathologyproven cases (Table 1) . It should be noted that clinical flow cytometry was insensitive in detecting DLBCL-a finding also reported by others, probably due to the fragile nature of large lymphoma cells 32 . 
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The low-grade lymphoma group (n = 15) comprised a mixture of follicular lymphoma (n = 9), small B cell lymphoma (n = 4) and mantle cell lymphoma (n = 2). CEM analyses determined two cases (cases 10 and 12; Supplementary Table 1 ) to be aggressive based on high Ki67 levels alone. After incorporating clinical information (size of mass lesions, adenopathy or clinical history), all cases were correctly diagnosed (Supplementary Table 2 ). CEM accurately diagnosed all 16 cases of benign adenopathy, while flow cytometry showed 1 false positive and 4 non-diagnostic cases.
Discussion
AIDS-related cancers, particularly lymphoma, are on the rise in Sub-Saharan Africa due to improved survival as a result of AIDS therapies [3] [4] [5] . Yet, due to limited resources, lymphoma and other Fig. 5 ) compared with advanced work-up (CD19, CD20, CD3, CD5, CD10, CD15, CD30, κ and λ light chains, Ki67, Pax5, Alk1, and cyclin D1), the diagnostic accuracy of CEM could also be improved. However, we decided not to pursue this at this time, as our primary objective was to validate the CEM method for deployment in Sub-Saharan Africa, which is disproportionately impacted by aggressive lymphomas due to a higher human immunodeficiency virus (HIV) incidence than in resource-rich regions such as North America 6, 7 . This approach could triage lymphomas into those that require prompt chemotherapy and those that do not.
The current research was designed as a feasibility study to develop and validate point-of-care technology for lymphoma diagnoses. For robust field testing in a resource-limited setting, we expect improvement in the following areas before rolling out to LMIC testing: (1) fewer steps for labelling and washing; (2) 
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NATure BiomedicAL eNgiNeeriNg simplified assembly and maintenance of devices; (3) more secure data transmission and storage; (4) protection against potential contamination; and (5) prospective validation or adjustments of the current decision tree algorithm in larger patient datasets. We used well-established antibody conjugates coupled to peroxidases or phosphatases, and chromogenic substrates such as ImmPACT VIP 33 . To simplify the various labelling and washing steps, we developed a disposable cartridge system to specifically capture and stain B cells. Using these cartridges, antibodies can be lyophilized and stored at preferred temperatures for weeks without degradation. This is an important factor for field testing. Once rehydrated, cell samples can be introduced into the system. A new self-contained cartridge that can process a 1.5 ml reservoir and limit fluid handling and contamination is under development for field testing ( Supplementary Fig. 9 ). Safe handling is critical when dealing with specimens in HIV-endemic areas. Modular hardwares (imaging parts, microcomputers and power supplies) and open-source softwares reduce costs and maintenance. 
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The CEM technology is based on a free-standing platform for data acquisition, communication and result display ( Fig. 1) . We built the system from inexpensive components that add up to a fraction of the cost of the smartphone used in a previous system 11, 28 , while also containing a high-resolution CMOS image sensor. The current system components include the CMOS (US$40), a touchscreen display (US$40), a Raspberry Pi computer with Bluetooth and WiFi (US$40) and various small parts (US$30). Costs total ~$180 per imaging system-one of the lowest-cost molecular diagnostic systems available even before economies of scale. While it is possible to perform holographic reconstruction directly on the Raspberry Pi computer, we opted for dual cloud-based integration to enable deep learning, speed up reconstruction and allow centralized input into the diagnostic output. The system allows diagnosis in < 1 min through the cloud and < 10 min without internet access. By comparison, diagnostic turnaround times for various cancers can take months (median: 160 d) in resource-constrained regions 34 . For the type of aggressive lymphoma for which CEM was designed, the Botswana Prospective Cancer Cohort identified a median time of 4 months (95% confidence interval: 2.1-11 months) between clinic visit and finalized diagnosis (unpublished data).
The current system is a first-generation platform that we intend to improve. Possible and planned upgrades and enhancements include implementing higher resolutions (or fields of view), multiplexing capabilities and adapting reagents to enable diagnoses of other malignancies, such as Hodgkin's lymphoma 35 or carcinomas. These changes should improve detection accuracies and allow for identifying sub-phenotypes. We also intend to extend the use of deep learning for rapid and accurate image analysis and diagnosis as we obtain more clinical data for training. In summary, we expect that our CEM technology will be highly beneficial in LMICs: at the least it will enable broad-based, decentralized patient triage (malignant versus benign adenopathy; and high-grade versus low-grade lymphoma), and at best it will provide detailed molecular analyses of lymphomas and other highly prevalent LMIC malignancies. Compared with flow cytometry and immunohistochemistry, the molecular diagnostics system reported here is significantly more cost-effective, operable by less-skilled health workers and wellsuited for point-of-care settings, health clinics and rural areas.
Methods
CEM device. The integrated CEM imaging unit is equipped with a 1.4 A highpower 625 nm light-emitting diode (LED) (Thorlabs) heat-sinked by a metal printed circuit board and a custom machined aluminium holder. A 220 grit optical diffuser (DGUV10; Thorlabs) is positioned between the LED and a 50 µ m pinhole (Thorlabs). Optical components are aligned by machined acrylonitrile butadiene styrene mounts. Images are captured using a monochromatic 10 megapixel CMOS image sensor (ON Semiconductor) mounted on a USB 3.0 interface board (The Imaging Source). The pixel size is 2.2 µ m and the FOV is 5.7 mm × 4.3 mm. Image data are transferred from the camera to a Raspberry Pi 3.0 (Broadcom BCM2837 SoC) running Debian Linux. An integrated seven-inch display (Raspberry PI Foundation) provides a real-time view of holographic data, and a touchscreen user interface captures and saves data. The touchscreen interface is written with the Kivy framework version 1.10 running on a Python 2.7.9 interpreter. Images can be directly transferred via WiFi to a cloud-based GPU server for analysis. The unit is powered by a regulated 18 V, 60 W adaptor (Meanwell) and runs continuously for approximately 2.5 h when powered by a 3-cell, 4.2 V/6.6 Ah Li+ battery pack. The device housing is three-dimensionally printed (Formlabs), and the machined aluminium door is fastened with 1/8 inch neodymium disc magnets (Grainger). The diffraction chamber is fabricated using opaque 1/8 inch acrylic sheets (laser ablation) and is light-proofed using flocking papers (Edmund Optics). The dimensions of the hardware unit are 205 mm (L) × 120 mm (W) × 175 mm (H), and the overall weight is 1.4 kg.
Cloud computing.
A central server (GPX XS8-2460V3-4GPU) is equipped with two six-core Intel Xeon processors (E5-2609 v3 1.90 GHz 15 MB Cache), 8 16 GB PC4-17000 2133 MHz DDR4 and a GPU (NVIDIA Kepler K80). The K80 GPU has 4,992 compute unified device architecture (CUDA) cores and 24 GB of GDDR5 memory. The operating system is based on Ubuntu Linux 14.04 LTS Server Edition 64-bit. The code is written in C+ + and uses vendor-provided modules (CUDA extensions, CUDA driver 7.0 and the cuFFT library). The imaging server periodically checks a dedicated folder in a cloud storage (Dropbox). When new images and image information are found, the server runs an image reconstruction. It then counts cells on the reconstructed frames. The reconstructed images and counting statistics are saved in a sub-folder on Dropbox. When a Dropbox client is synchronized, the image and data files can be accessed. All collected information is organized and stored in a secure web-based system (CSB Trials; Supplementary  Fig. 10 ) that supports multi-modal images in raw format. The developed in-house system is a multi-tier application that utilizes the Ruby on Rails framework. All software is built using open-source modules. Data are stored in the MySQL database; image conversions utilize dicomlib and ImageMagick.
Software architecture and deep learning. To detect B cells using deep learning, we implemented three modules that operate on a hologram image: the maximally stable extremal regions (MSER) blob detection algorithm, faster non-maximum suppression algorithm and CNN. The MSER blob detection algorithm finds celllike regions based on six parameters, including region size, shape and intensities.
Once regions are proposed by the MSER algorithm, the bounding box coordinates are filtered by a non-maximum suppression algorithm with a maximum overlap threshold of 0.25. The remaining boundary box coordinates are mapped to a hologram input image, and each region is passed as input to the trained CNN for classification. The CNN was trained to classify a region as either containing one or more cells, or containing no cells.
To train the CNN, the Adam optimization algorithm 36 was used to iteratively tune the weights in each CNN layer by calculating the CNN's loss at each iteration with respect to the ground-truth labels of each training example with the binary cross-entropy loss function. The training set was generated using the MSER algorithm to detect regions from sample hologram images of cells, and each region was categorized as either 'cell-like' or 'non-cell' . The total size of the training set was 2,661 non-cell hologram regions and 2,509 cell-like hologram regions. The training set was split into 3,447 training samples and 1,723 validation samples. We used an Amazon Web Services p2.xlarge server with a Nvidia Kepler K80 GPU to run the training process over the entire training set for 250 epochs. All code was written using Python 3.6.1. Supplementary Fig. 3 shows a decision tree used to analyse sample parameters. The B cell population cut-off was obtained from a previous pilot study 28 while the clonality, Ki67 level and size were defined by consulting the literature [29] [30] [31] and standard operating procedures of flow cytometry at our institution. All parameters were then used prospectively in the current study. Specifically, the 20% CD19/20-positive B cell population cut-off was based on a previous study 28 . This assures that sufficient numbers of B cells are present in a given sample to determine the clonality; however, by itself, the cut-off does not have any discriminatory power. The threshold for clonality was set to 0.5 ± 0.05 (for κ dominant) and -0.5 ± 0.05 (for λ dominant) after reviewing the published literature 29 and World Health Organization guidelines 30, 31 . To be classified as lymphoma, a given sample had to have a B cell population of over 20% of total cells and a monoclonal B cell population (either κ or λ dominant). To pass quality assurance, we also defined a minimum number of cells (100 cells) for a given measurement, and at least 10% of total cells had to be positive for κ , λ or Ki67. Table 3 lists the antibodies used in the study. For pointof-care operation, we further tested lyophilized antibodies. Antibodies (0.7 mg ml -1 , Ki67) were lyophilized using a freeze-dryer (FreezeMobile 25 EL; SP Scientific). The lyophilized antibodies were vacuum-sealed and then tested in different storage conditions (-20, 4, 25 and 37 °C; Fig. 4c ). The functionality of the lyophilized antibodies was tested and compared with fresh non-lyophilized antibodies. The glass substrates in flow cells were also lyophilized under the same conditions. Following rehydration with 60 µ l of Milli-Q water, cartridges and antibodies could be used without additional modifications.
Diagnostic decision tool.
Reagents. Supplementary
Cell lines. Daudi (Burkitt's lymphoma), DB (germinal centre B cell like DLBCL)
and Jurkat (T cell leukaemia) cell lines were purchased from the American Type Culture Collection (ATCC). All cell lines were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated foetal bovine serum, 100 IU penicillin and 100 µ g ml -1 streptomycin at 37 °C under a humidified atmosphere of 5% CO 2 . Cell lines were routinely tested for mycoplasma contamination using a MycoAlert Mycoplasma Detection Kit (Lonza).
Optimization of staining assay. For assay optimization and validation, we performed a number of experiments in cell lines before moving to clinical samples (see below). We specifically tested: (1) different antibodies; (2) different substrates;
(3) different staining conditions; (4) environmental influences and reagent stability; and (5) different flow chambers and reproducibility. Supplementary Fig. 11 summarizes the assay procedure. In general, harvested cells were fixed with 1× Lyse/Fix buffer (BD Biosciences) and incubated with biotinylated anti-human CD19 and CD20 antibodies (10 µ g ml -1 ). Cells were then permeabilized (0.005% saponin) and labelled with anti-human IgG κ light chain, IgG λ light chain or Ki67 antibodies (10 µ g ml -1 ) followed by horseradish peroxidase (HRP) anti-rabbit IgG secondary antibody. Labelled cells were Articles NATure BiomedicAL eNgiNeeriNg introduced into flow cells and incubated for 30 min. B cells labelled with biotinylated anti-CD19/CD20 antibodies were captured on the neutravidin-coated surface of flow cells, and unbound cells were removed by washing at 40 ml h -1 for 1 ml. Captured cells were stained with ImmPACT VIP Peroxidase (HRP) Substrate (Vector Labs) for 15 min. Three images per sample (pre-wash, post-wash and stained) were taken using the CEM device. The antibodies used are listed in Supplementary Table 1 . The assay buffer consisted of phosphate buffered saline (PBS) supplemented with 2% bovine serum albumin (BSA) and 2% foetal bovine serum. Samples were tested immediately, or occasionally stored at − 80 °C in PBS (2% BSA) for future comparative use.
Flow cell cartridge. We designed flow cells using glass cover slips and sticker-type hybridization chambers to simplify fluid handling and staining. For field testing, we developed flow cells with 1.5 ml reservoirs. The acrylic top cover was fabricated via laser ablation (Epilog 120 W) of a clear 1.6 mm ultraviolet-resistant acrylic sheet. The silicone chamber was fabricated from a 0.8 mm high-temperature silicone sheet via laser ablation. The plastic base, including the reservoir chamber, was created by stereolithographic printing with a clear photopolymer resin (Formlabs). A 25 mm × 25 mm glass coverslip (Gold Seal) was held in place by pressure fit between the silicone chamber and plastic base. The glass surface was first treated with 2% (3-aminopropyl)triethoxysilane (APTES; Sigma-Aldrich) for 30 min followed by 2.5% (v/v) glutaraldehyde in PBS (Sigma-Aldrich) for 2.5 h. A sticker-type hybridization chamber (9 mm diameter and 0.6 mm depth; Sigma-Aldrich) was used to confine the imaging area and the assay volume down to 60 µ l. Finally, neutravidin (100 µ g m -1 ) was permanently immobilized on the aldehydefunctionalized surface via reductive amination reaction using 4.5 mM sodium cyanoborohydride. The surface was washed extensively with PBS, then blocked with 1% BSA in PBS for 1 h. The flow cell cartridges with neutravidin were also lyophilized using the same protocol as for the antibodies. For CEM measurements, the flow cell was aligned and placed on top of the image sensor. The gap distance between the flow cell and image sensor was approximately 0.5 ± 0.03 mm, which was estimated by our detection algorithm. For each sample, three flow cells were used for κ , λ and Ki67, and were disposed of after the measurements.
Flow cytometry. To benchmark the CEM measurements, we performed correlative flow cytometry using lymphoma cell lines. Half a million cells were prepared per marker using the same procedure as for CEM, except Alexa Fluor 488-conjugated secondary antibody was used instead of the HRP secondary antibody. Fluorescent signals were measured using a BD LSR II Flow Cytometer (BD Biosciences) and normalized against isotope controls. Flow cytometry of clinical samples was performed by hospital Department of Pathology clinicians (see below and Supplementary Table 2 ).
Patient study and clinical sample processing. We performed a prospective diagnostic study in which an FNA sample was obtained during clinically indicated image-guided FNA/biopsy of nodal mass lesions. This study and related materials (such as a consent form) were reviewed and approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board. The investigators and other research staff ensured full study compliance with all relevant ethical regulations. Patients referred to the Division of Interventional Radiology at Massachusetts General Hospital because of clinically suspected new or recurrent lymphoma were enroled following informed consent. Either ultrasound or computed tomography guidance was used to confirm the correct needle position within a suspicious lymph node. Four to eight coaxial FNA passes yielded material for flow cytometry, cytopathology and CEM analysis. Additional core biopsies were obtained for conventional pathology work-up, which served as the gold standard alongside clinical information. For CEM analysis, FNA samples were fixed with 1× BD Phosflow Lyse/Fix buffer (BD Biosciences) and then processed as described for cell lines. CEM analyses were conducted blinded to conventional pathology, and vice versa. Corresponding author(s): Ralph Weissleder Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.
Experimental design 1. Sample size
Describe how sample size was determined.
The current study was designed to prospectively obtain fresh samples and then closely correlate them to pathological and clinical information. More specifically, the study was designed to prospectively enroll patients over a one year period with suspicion for new or recurrent lymphoma referred to the Division of Interventional Radiology at Massachusetts General Hospital following informed consent. Limited available data also prevented us from performing formal power analysis to determine sample size. Rather, it was designed to generate data to inform future confirmative studies.
Data exclusions
Describe any data exclusions.
No data were excluded.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
The reproducibility of assays were tested in multiple times by using cell lines. In the assayoptimization process, we specifically tested i) different antibodies, ii) different substrates, iii) different staining conditions, iv) environmental influences and stability of reagents, v) different flow chambers and reproducibility. All measured data were compared with goldstandard methods (flow cytometry and pathology work-up).
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Patients with clinical suspicion for new or recurrent lymphoma referred to the Division of Interventional Radiology at Massachusetts General Hospital were enrolled following informed consent in randomized allocation.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis. CEM analyses were conducted blinded to conventional cytology/pathology, and viceversa. Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed). n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons Test values indicating whether an effect is present Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
For the CEM device, a Raspberry PI 3.0 (Broadcom BCM2837 SoC) running Debian Linux was used. The touch-screen interface is written with the Kivy framework v1.10 running on a Python 2.7.9 interpreter. The clouding server was based on Ubuntu Linux 14.04 LTS Server Edition 64-bit. The code was written in C++ and used vendor-provided modules (CUDA extensions, CUDA driver 7.0, CUFFT library). We used an Amazon Web Services p2.xlarge server with an Nvidia Kepler K80 GPU to run the deep-learning training process, and all code was written using Python 3.6.1. Prism 7 was used for statistical analyses and data ploting.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
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